Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.66 |
| ▸ | NPC1 | O15118 | 7/20 | 0.66 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TLR4 | O00206 | 1/20 | 0.56 |
| ▸ | TLR2 | O60603 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | PKM | P14618 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2943454 | 0.85 | RAB9A (0.66) | RAB9ANPC1SIRT2MEN1KMT2A | |
| SCHEMBL18398683 | 0.83 | SIRT2 (0.57) | SIRT2MEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL3365984 | 0.83 | RAB9A (0.83) | RAB9ANPC1MEN1KMT2AGRM5 | |
| SCHEMBL18398740 | 0.82 | TSHR (0.66) | RAB9ANPC1SIRT2MEN1KMT2A | |
| SCHEMBL16964864 | 0.82 | NAMPT (0.50) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL997866 | 0.82 | RAB9A (0.89) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29366822 | 0.82 | RAB9A (0.89) | RAB9ANPC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7348632 | 0.82 | RAB9A (0.66) | RAB9ANPC1SIRT2MEN1KMT2A | |
| SCHEMBL2946989 | 0.82 | NPC1 (0.71) | RAB9ANPC1SIRT2MEN1KMT2A | |
| SCHEMBL8556579 | 0.82 | GRM5 (0.67) | RAB9ANPC1SIRT2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57206661-A | — | — | None | — | — | JP | disclosed |
| US-20240246915-A1 | AMINONAPHTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-07-25 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| EP-3324954-B1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO LTD (TW) | 2022-03-09 | — | — | EP | disclosed |
| EP-3324954-B1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO LTD (TW) | 2022-03-09 | — | — | EP | disclosed |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-05-14 | — | — | US | disclosed |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-05-14 | — | — | US | disclosed |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-03-03 | — | — | US | disclosed |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-03-03 | — | — | US | disclosed |
| US-20180319749-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2018-11-08 | — | — | US | disclosed |
| EP-3324954-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | Taipei Medical University (TW) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017014788-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | TAIPEI MEDICAL UNIVERSITY (CN) | 2017-01-26 | — | — | WO | disclosed |
| US-6638921-B1 | Pharmaceutically acceptable derivatives thereof Cx, R1 and R2 being as defined in the disclosure may be used to inhibit the activity of HIV integrase. | PHARMACOR INC. (CA) | 2003-10-28 | — | — | US | disclosed |
| WO-2003082881-A2 | PYRIDOXAL-5-PHOSPHATE DERIVATIVES AS HIV INTEGRASE INHIBITORS | PROCYON BIOPHARMA INC. (CA) | 2003-10-09 | — | — | WO | disclosed |
| EP-0077534-B1 | BENZAMIDE DERIVATIVES, A PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 1987-01-14 | — | — | EP | disclosed |
| US-4500714-A | ANTIDIABETIC AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1985-02-19 | — | — | US | disclosed |
| EP-0077534-A2 | Benzamide derivatives, a process for preparing the same, and pharmaceutical compositions containing the same | Chugai Seiyaku Kabushiki Kaisha (JP) | 1983-04-27 | — | — | EP | disclosed |
| JP-S57206661-A | ACETAMINOBENZAMIDE DERIVATIVE | CHUGAI PHARMACEUT CO LTD | 1982-12-18 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | RAB9A 1327/4885NPC1 2017/4885SIRT2 3191/4885 |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | PSMB1, UBQLN1, PSMB5 | RAB9A 1133/4885NPC1 2272/4885SIRT2 2935/4885 |
| US-20180319749-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | RAB9A 1327/4885NPC1 2017/4885SIRT2 3191/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | RAB9A 1238/4885NPC1 1274/4885SIRT2 3432/4885 |
| US-20240246915-A1 | AMINONAPHTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, ADRM1, UBQLN2 | RAB9A 967/4885NPC1 1072/4885SIRT2 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.